ArticleBlood2019
Recurrent
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 66 citations in OpenAlex.
- Article
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.Leukemia · 2025Article
- Review
- Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.Blood advances · 2024Article
- Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.Research square · 2024Article
- Diagnostic and prognostic molecular pathology of lymphoid malignancies.Virchows Archiv : an international journal of pathology · 2024Review
- Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.Pathologie (Heidelberg, Germany) · 2023Review
- Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.Current hematologic malignancy reports · 2023Review
- Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.Haematologica · 2023Review
- What is new in the classification of peripheral T cell lymphomas?Pathologie (Heidelberg, Germany) · 2023Review
- Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation.Human pathology · 2023Article
- Article
- ALK-negative anaplastic large cell lymphoma withHaematologica · 2023Article
- Mature T-cell and NK-cell lymphomas: updates on molecular genetic features.International journal of hematology · 2023Review
- SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities.Molecular cancer · 2023Review
- Updates in pathobiological aspects of anaplastic large cell lymphoma.Frontiers in oncology · 2023Review
- How molecular advances may improve the diagnosis and management of PTCL patients.Frontiers in oncology · 2023Review
- Targeted panel sequencing in the routine diagnosis of mature T- and NK-cell lymphomas: report of 128 cases from two German reference centers.Frontiers in oncology · 2023Article
- Types of T-cell lymphoma-a cytogenetic perspective.Annals of medicine and surgery (2012) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 4 countries.
Rebecca A LuchtelDepartment of Laboratory Medicine and Pathology and.ORCID 0000-0002-7523-5010
Michael T ZimmermannDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.ORCID 0000-0001-7073-0525
Guangzhen HuDepartment of Laboratory Medicine and Pathology and.
Surendra DasariDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Manli JiangDepartment of Laboratory Medicine and Pathology and.
Naoki OishiDepartment of Laboratory Medicine and Pathology and.
Hailey K JacobsDepartment of Laboratory Medicine and Pathology and.
Yu ZengDepartment of Laboratory Medicine and Pathology and.
Tanya HundalDepartment of Laboratory Medicine and Pathology and.
Karen L RechDepartment of Laboratory Medicine and Pathology and.
Rhett P KetterlingDepartment of Laboratory Medicine and Pathology and.
Jeong-Heon LeeDepartment of Laboratory Medicine and Pathology and.ORCID 0000-0003-4007-9166
Bruce W EckloffMedical Genome Facility, Mayo Clinic, Rochester, MN.
Huihuang YanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Krutika S GaonkarDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Shulan TianDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Zhenqing YeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Marshall E KadinDepartment of Dermatology, Roger Williams Medical Center, Providence, RI.
Jagmohan SidhuDepartment of Pathology and Laboratory Medicine, United Health Services Hospitals, Johnson City/Binghamton, NY.
Liuyan JiangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0002-9851-985X
Jesse VossDepartment of Laboratory Medicine and Pathology and.
Brian K LinkDepartment of Internal Medicine and.
Sergei I SyrbuDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.
Fabio FacchettiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; and.
N Nora BennaniDivision of Hematology, Mayo Clinic, Rochester, MN.
Susan L SlagerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Tamas OrdogEpigenomics Program, Center for Individualized Medicine and.ORCID 0000-0002-3940-7284
Jean-Pierre KocherDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.ORCID 0000-0002-7482-178X
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology and.ORCID 0000-0001-5009-4808
Mayo Clinic in Florida · USMayo Clinic in Arizona · USJacksonville College · USRoger Williams Medical Center · USTongji University · CNUnited Health Services · USUniversity of Brescia · ITUniversity of Iowa Hospitals and Clinics · USUniversity of Yamanashi · JP
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MThe Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MGenetic Biomarkers for Risk Assessment of Peripheral T-Cell LymphomasR01CA177734 · NCI · MAYO CLINIC ROCHESTER · PI FELDMAN, ANDREW LEWIS · 2013 to 2017
$1.6MNCATS NIH HHS UL1 TR000135NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA177734
Abstract
Anaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked genetic heterogeneity. ALCLs are broadly classified as being anaplastic lymphoma kinase (ALK)
Indexed as
Anaplastic Lymphoma KinaseBasic Helix-Loop-Helix ProteinsCell CycleGene Expression Regulation, NeoplasticHumansLymphoma, Large-Cell, AnaplasticMutationALK protein, humanAnaplastic Lymphoma KinaseBasic Helix-Loop-Helix ProteinsMSC protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.